Serum sclerostin levels in renal cell carcinoma patients with bone metastases

Sclerostin has been proposed as a potent inhibitor of bone formation. Sclerostin antibodies are under clinical development to treat osteoporosis and metastatic bone disease. Serum sclerostin level is elevated in multiple myeloma, an osteolytic malignancy, where it might serve as predictive marker fo...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2016-09, Vol.6 (1), p.33551-33551, Article 33551
Main Authors: Wibmer, C., Amrein, K., Fahrleitner-Pammer, A., Gilg, M. M., Berghold, A., Hutterer, G. C., Maurer-Ertl, W., Gerger, A., Leithner, A., Pichler, M., Szkandera, J.
Format: Article
Language:English
Subjects:
692/4028/546
692/4028/67/322/803
Antibodies
Bone growth
Enzyme-linked immunosorbent assay
Epidermal growth factor receptors
Glomerular filtration rate
Glycoproteins
Humanities and Social Sciences
Kidney cancer
Malignancy
Metastases
Metastasis
multidisciplinary
Multiple myeloma
Osteogenesis
Osteolysis
Osteoporosis
Renal cell carcinoma
Science
SOST protein
Variance analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sclerostin has been proposed as a potent inhibitor of bone formation. Sclerostin antibodies are under clinical development to treat osteoporosis and metastatic bone disease. Serum sclerostin level is elevated in multiple myeloma, an osteolytic malignancy, where it might serve as predictive marker for the use of sclerostin-directed antibodies. As renal cell carcinoma (RCC) patients often present with osteolytic metastases, we aimed to investigate serum sclerostin levels in RCC patients. Our study included 53 RCC patients (19 with bone metastases, 25 with visceral metastases and 9 with localized disease) and 53 age- and gender-matched non-osteoporotic controls. Frozen serum samples were subjected to sclerostin quantitative sandwich ELISA. The mean serum sclerostin levels of RCC patients and controls were 45.8 pmol/l and 45.1 pmol/l, respectively (p = 0.86). Analysis of variance showed no difference between the subgroups of RCC patients with regard to visceral or bone metastases or localized disease (p = 0.22). There was no significant association between eGFR (estimated glomerular filtration rate) and serum sclerostin levels in RCC patients (r = 0.05; p = 0.74) and controls (r = 0.06; p = 0.68). Our results indicate that serum sclerostin levels appear not to be a valuable biomarker to assess the occurrence of bone metastases in RCC patients.
ISSN:2045-2322
2045-2322
DOI:10.1038/srep33551